Introduction: Small intestine neuroendocrine tumors (SI-NETs) are rare fatal cancers. Many patients develop metastatis before diagnosis. There is no available curative treatment for patients with metastasis.
Aim(s): Ma2 is a new SI-NET biomarker. The goal is to evaluate whether anti-Ma2 detection in the blood is useful for clinical patient management.
Materials and methods: A novel indirect enzyme-linked immunosorbent assay (ELISA) was set up to detect Ma2 autoantibodies in blood. One-hundred and ninety blood samples from patients with SI-NET, typical and atypical lung carcinoids, different stage of disease, were used. Immunohistochemistry, Western blot, Sequential Immunoprecipitation and Immuno-Dot-blot analyses were used in the study.
Conference: 8th Annual ENETS Conference (2011)
Presenting Author: Associate Profes Valeria Giandomenico
To read results and conclusion, please login ...
Further abstracts you may be interested in